Project Grant R44DA050357

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify small-molecule compounds that can selectively modulate the G9A protein complex, which regulates the expression of DFosB in the brain during chronic opioid exposure. The work will involve a...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to identify small molecule compounds that can bind to the GPR26 receptor and potentially treat opioid use disorders (OUDs) without directly targeting opioid receptors. The $399,884 award to Jillion Therapeutics Inc. will utilize DNA-encoded library (DEL) screening technology to test over 125 million proprietary compounds for high-affinity...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The $399,414 award will fund the development of an AI-powered platform called M3.AI that integrates target-based and phenotype-based drug discovery methodologies. The platform will generate multi-cell type, multi-objective,...

This federal Cooperative Agreement award of $11,872,077 from the National Institute on Drug Abuse (NIDA) under the CFDA 93.279 Drug Use and Addiction Research Programs supports the development of SBS-226, a novel mu-opioid receptor (MOR) agonist and delta-opioid receptor (DOR) antagonist compound, for the treatment of opioid use disorder (OUD). The award, with a performance period from September 30, 2024 to August 31, 2026, will fund the completion of IND-enabling studies and a Phase 1...

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a treatment for opioid use disorder (OUD). The award supports screening of next-generation compounds targeting the metabolic enzyme ACSS2, which has been shown to play a key role in the encoding of drug-related memories. This research aims to identify a potent ACSS2 inhibitor that...

This federal Project Grant award of $1,594,478, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a 5-year observational study of craving patterns and digital phenotyping in individuals with opioid use disorder (OUD) initiating medication-based treatment (MOUD). The key objective is to develop clinically-informed digital biomarkers and phenotypes that can predict MOUD outcomes. The study will monitor 300...

The National Institute on Drug Abuse (NIDA) awarded Labsys LLC a $643,948 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The objective is to create a low-cost, painless patch that can monitor medication levels in interstitial fluid to provide real-time insights into the effectiveness of opioid use disorder treatment protocols. The initial Phase I research will focus on...

This $399,483 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to generate synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel multivalent compounds for treating substance use disorders (SUDs). The key objectives are to: 1) use DEL screening to identify compounds that target the opioid receptor delta (OPRD1) and dopamine receptor D3 (DRD3) to...

This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), will support the development and evaluation of a digital platform to improve the delivery of opioid risk screening and safety interventions in community pharmacies. The $591,752 award will fund a collaboration between OPREMS LLC and North Dakota State University to integrate an existing paper-based screening tool into a tablet-based digital platform....

The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant, with a performance period from April 1, 2025 to March 31, 2026, is for the development of a "Rapid Fingerstick Diagnostics for Opioid and Stimulant Use Disorders." This project aims to address the escalating public health crisis of opioid and stimulant use...